Compare Sunrun Inc (RUN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Sunrun Inc trades at $7.63 (market cap $1.83B), while State Street SPDR S&P Biotech ETF trades at $149.89 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5.5× Sunrun Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sunrun Inc for 16 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| RUN | XBI | |
|---|---|---|
Market Cap | $1.83B | $10.11B |
Volume | 8,672,852 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $21.41 | $169.55 |
52-Week Low | $7.59 | $104.99 |
Typical Hold Time | 16 Days | 37 Days |
Enterprise Value | $16.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $7.61, down 2.06% amid broader solar sector weakness. The stock shows bearish technical signals with resistance at $8, while fundamentals reveal mixed results: strong valuation metrics (P/E 5.16, P/S 0.59) contrast with negative operating cash flow and high debt levels. Recent positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.
Despite attractive valuations and analyst optimism (62% buy rating, $16.56 target), RUN faces significant headwinds from high borrowing costs impacting solar financing, weak underlying business trends, and persistent cash burn. The stock presents a high-risk opportunity with substantial upside potential if execution improves, but requires careful monitoring of cash flow stabilization and subscriber growth metrics.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
